JACC White Paper
Lone Atrial Fibrillation: Does it Exist?

https://doi.org/10.1016/j.jacc.2014.01.023Get rights and content
Under an Elsevier user license
open archive

The historical origin of the term “lone atrial fibrillation” (AF) predates by 60 years our current understanding of the pathophysiology of AF, the multitude of known etiologies for AF, and our ability to image and diagnose heart disease. The term was meant to indicate AF in patients for whom subsequent investigations could not demonstrate heart disease, but for many practitioners has become synonymous with “idiopathic AF.” As the list of heart diseases has expanded and diagnostic techniques have improved, the prevalence of lone AF has fallen. The legacy of the intervening years is that definitions of lone AF in the literature are inconsistent so that studies of lone AF are not comparable. Guidelines provide a vague definition of lone AF but do not provide direction about how much or what kind of imaging and other testing are necessary to exclude heart disease. There has been an explosion in the understanding of the pathophysiology of AF in the last 20 years in particular. Nevertheless, there are no apparently unique mechanisms for AF in patients categorized as having lone AF. In addition, the term “lone AF” is not invariably useful in making treatment decisions, and other tools for doing so have been more thoroughly and carefully validated. It is, therefore, recommended that use of the term “lone AF” be avoided.

Key Words

idiopathic atrial fibrillation
lone atrial fibrillation
white paper

Abbreviation and Acronym

AF
atrial fibrillation

Cited by (0)

Dr. Wyse has received honoraria for serving on data and safety advisory boards for randomized clinical trials sponsored by Boehringer Ingelheim, Bristol Myers Squibb/Pfizer, Sanofi Aventis, Biotronik, Boston Scientific/Guidant (Europe), Medtronic, Merck, and St. Jude Medical. Dr. Ellinor is supported by grants from the National Institutes of Health (R01HL092577, R01HL104156, 1K24HL105780) and the American Heart Association (13EIA14220013). Dr. Go has received research support from iRhythm. Dr. Kalman has received fellowship or research support from Medtronic, St. Jude Medical, Biosense Webster, and Boston Scientific. Dr. Narayan is supported by a grant from the National Institutes of Health (HL103800); is coauthor of intellectual property owned by the University of California Regents and licensed to Topera Inc. (Topera does not sponsor any research, including that presented here) and holds equity in Topera; and reports having received honoraria from Medtronic, St. Jude Medical, and Biotronik. Dr. Rienstra is supported by a grant from the Netherlands Organization for Scientific Research (Veni grant 016.136.055). There was no financial support for this work other than that provided by the Journal for the meeting in Denver during Heart Rhythm 2013. All other authors have reported they have no relationships relevant to the contents of this paper to disclose.